Endometrial Cancer: Counseling on dMMR vs pMMR - Explaining Survival Advantage and Clinical Expectations

When counseling patients, distinguishing between dMMR and pMMR tumors is essential because these groups experience different levels of benefit from immunotherapy. Patients with dMMR disease frequently show strong and durable responses, contributing to a clearer survival advantage and greater long term optimism.For pMMR tumors, the benefit of chemo immunotherapy is more modest, but it remains clinically meaningful. Clinicians often highlight that while the improvement may be smaller, it is still important for many patients. The addition of PARP immunotherapy combinations in DUO E introduces another potential strategy for selected pMMR patients, particularly those with specific molecular alterations. These evolving data help refine how providers explain prognosis and treatment expectations across both molecular subgroups.